Octylonium Bromide A PAF-R inhibitor

Octylonium Bromide  (CAS 26095-59-0)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 172ms
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
| See product citations (3)
Application: A PAF-R inhibitor
CAS Number: 26095-59-0
Purity: 98%
Molecular Weight: 563.6
Molecular Formula: C29H43N2O4Br
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ordering Information

Octylonium Bromide sc-201035 5 mg $154.00
Octylonium Bromide sc-201035A 25 mg $583.00

Octylonium Bromide has been reported to antagonize PAF (platelet-activating factor) induced aggregation of rabbit platelet-rich plasma, hypotension in rats, lethality in mice, and bronchoconstriction in guinea-pigs. This compound also demonstrates the ability to potently block neuronal nicotinic acetylcholine receptors and also a mild wide-spectrum Ca2+ channel blocker in bovine adrenal chromaffin cells. Additionally, Octylonium Bromide has been shown to inhibit muscular action potentials carried by L-type Ca2+ current. Octylonium Bromide is an inhibitor of PAF-R.


1. Subissi, A., et al. 1989. Arch Int Pharmacodyn Ther. 302: 255-267. PMID: 2636821
2. Gandía, L., et al. 1996. Br. J. Pharmacol. 117: 463-470. PMID: 8821535
3. Martin, M.T., et al. 2004. Neurogastroenterol. Motil. 16: 175-183. PMID: 15086871

Physical State :
Solubility :
Soluble in water (12 mg/mL), DMSO (>25 mg/mL), ethanol (>25 mg/mL), and methanol.
Storage :
Store at -20° C
Melting Point :
166-168° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
EC Number :

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

You May Also Like

Octylonium Bromide Product Citations

See how others have used Octylonium Bromide. Click on the entry to view the PubMed entry .

Citations 1 to 3 of 3 total

PMID: # 15086870
Strege, PR. et al. 2004. Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle. Neurogastroenterol. Motil.. 16: 167-173.

PMID: # 9798806
Battaglia, G. et al. 1998. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment. Pharmacol. Ther.. 12: 1003-1010.

PMID: # 3168757
Manzini, S. et al. 1988. Further studies on the pharmacodynamic properties and organ selectivity of octylonium bromide. Drugs Exp Clin Res. 14: 265-270.

Citations 1 to 3 of 3 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 62ms
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2017 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.